abstract |
The present invention provides human antibodies that bind to human CSF-1R with high affinity. Antibodies of the present invention have significant advantages over antibodies known in the art by the following multifunctionalities: inhibition of signaling of CSF-1R in cells including tumors, macrophages and monocytes, internalization of CSF-1R degradation And induction and stimulation of ADCC. They may also be used alone or in docetaxel, paclitaxel, herceptin ? Or in combination with doxorubicin has been found to be effective in treating leukemia, breast cancer, endometrial cancer and prostate cancer. |